Management of hirsutism

American Journal of Clinical Dermatology

Volumn 1, Issue 2, 2000, Pages 89-99

  Falsetti, Leopoldo ^a,b   Gambera, Alessandro ^a   Platto, Chiara ^a   Legrenzi, Laura ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADOTROPIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; DRUG POTENTIATION; FEMALE; HIRSUTISM; HUMAN; REVIEW;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GONADOTROPINS; HIRSUTISM; HUMANS;

EID: 0034157725     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001020-00003     Document Type: Article

References (70)

1. Knochenhauer ES, Azziz R. Advances in the diagnosis and treatment of the hirsute patient. Curr Opin Obstet Gynecol 1995; 7: 344-50
2. Azziz R, Ochoa T. Idiopathic hirsutism (IH): an uncommon cause of hirsutism in Alabama [abstract P 075]. 53rd Annual Meeting of the American Society or Reproductive Medicine; 1997 Oct 18-22; Cincinnati
3. Carmina E. Prevalence of idiophatic hirsutism. Eur J Endocrinol 1998; 139: 421-3
4. Maroulis GB. Evaluation of hirsutism and hyperandrogenemia. Fertil Steril 1981; 36: 273-305
5. Rittmaster RS, Loriaux DL. Hirsutism. Ann Intern Med 1987; 106: 95-107
6. Serafini P, Lobo RA. Increased 5-alpha reductase activity in idiopathic hirsutism. Fertil Steril 1985; 43: 74-8
7. Barbieri RL. Polycystic ovarian disease. Annu Rev Med 1991; 42: 199-204
8. Ehrman DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrinol Rev 1995; 16: 322-53
9. Goldzieher JW, Green JA. The polycystic ovary: clinical and histologic features. J Clin Endocrinol Metab 1962; 22: 325-38
10. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol 1989; 30: 459-70
11. Prevelic G. Insulin resistance in polycystic ovary syndrome. Curr Opin Obstet Gynecol 1997; 9: 193-201
12. Acièn P, Quereda F, Matallin P, et al. Insulin, androgens and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32-40
13. Falsetti L, Eleftheriou G. Hyperinsulinemia in the polycystic ovary syndrome: a clinical, endocrine and echographic study in 240 patients. Gynecol Endocrinol 1996; 10: 319-26
14. Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor 1 stimulate the proliferation of human ovarian theca-interstitial cells. Fertil Steril 1998; 69: 335-40
15. Paulson RJ, Serafini PC, Catalino JA, et al. Measurements of 3α,17β-androstanediol glucuronide in serum and urine and the correlation with skin 5α-reductase activity. Fertil Steril 1986; 46: 222-6
16. Falsetti L, Rosina B, De Fusco D. Serum levels of 3α-androstanediol glucuronide in hirsute and non hirsute women. Eur J Endocrinol 1998; 138: 385-9
17. Jahanfar S, Eden JA, Warren P, et al. A twin study of polycystic ovary syndrome. Fertil Steril 1995; 63: 478-86
18. George FW, Russel DW, Wilson JD. Feed-forward control of prostatic growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase. Proc Natl Acad Sci USA 1991; 88: 8044-7
19. Lobo RA. Hirsutism in polycystic ovary syndrome: current concepts. Clin Obstet Gynecol 1991; 34: 817-25
20. Loho RA, Kletzky OA. Normalization of androgen and sex hormone binding globulin levels after treatment of hyperprolactinemia. J Clin Endocrinol Metab 1983; 56: 562-8
21. Danilenko DM, Ring BD, Pierce GF. Growth factors and cytokines in hair follicle development and cycling: recent insights from animal models and the potentials for clinical therapy. Mol Med Today 1996; 2: 460-7
22. Andersson S, Bishop RW & Russell DW, Expression, cloning and regulation of the steroid 5α-reductase, an enzyme essential for male sexual differentiation. J Biol Chem 1989; 264: 16249-55
23. Andersson S, Berman DM, Jenkins EP, et al. Deletione of the steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991; 354: 159-61
24. Mestayer CH, Berthaut I, Portois MC, et al. Predominant expression of 5α-reductase type 1 in pubic skin from normal subjects and hirsute patients. J Clin Endocrinol Metab 1996; 81: 1989-93
25. Roger S, Rittmaster MD. Finasteride. N Engl J Med 1994; 330: 120-5
26. Harris G, Azzolina B, Baginsky W, et al. Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc Natl Acad Sci USA 1992; 89: 10787-91
27. Moore RJ, Wilson JD. Steroid 5α-reductase in cultured human fibroblasts: biochemical and genetic evidence for two distinct enzyme activities. J Biol Chem 1976; 251: 5895-900
28. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341: 491-7
29. Adams J, Polson DW, Abdulwahid N, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; 2: 1375-8
30. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in woman. J Clin Endocrinol Metab 1961; 21: 1440-8
31. Chang RJ, Laufer RL, Meldrum DR, et al. Steroid secretion in polycystic ovarian desease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983; 56: 897-904
32. Wilson EE, Little BB, Byrd W, et al. The effect of gonadotropin-releasing hormone agonists on adrenocorticotropin and cortisol secretion in premenopausal women. J Clin Endocrinol Metab 1993; 76: 162-9
33. Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil Steril 1994; 61: 817-22
34. Cagnacci A, Paoletti AM, Arangíno S, et al. Effect of ovarian suppression on glucose metabolism of young lean women with or without ovarian hyperandrogenism. Hum Reprod 1999; 14: 893-7
35. Morcos RM, Abdul-Malak ME, Shikora E. Treatment of hirsutism with gonadotropin-releasing hormone agonist and estrogen replacement therapy. Fertil Steril 1994; 61: 427-31
36. Carmina E, Janni A, Loho RA. Physiological estrogen replacement may enance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. J Clin Endocrinol Metab 1994; 78: 126-30
37. Heiner JS, Greendale GA, Kawakami AK, et al. Comparison of gonadotropin-releasing hormone agonist and low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab 1995; 80: 3412-8
38. Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with gonadotropin-releasing hormone agonist (Naferelin). J Clin Endocrinol Metab 1986; 63: 854-9
39. Suikkari AM, Tiitinen A, Stenman UH, et al. Oral contraceptives increase IGFBP-1 in women with polycystic ovarian disease. Fertil Steril 1991, 55: 895-9
40. Porcile A, Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril 1991; 55: 877-81
41. Falsetti L, Ramazzotto F, Rosina B. Efficacy of combined ethinyloestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome. J Obstet Gynecol 1997; 17: 565-8
42. Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 1990; 42: 611-9
43. Brogden RN, Clissold SP. Flutamide: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. Drugs 1989; 38: 185-203
44. Pucci E, Genazzani AD, Monzani F, et al. Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol Endocrinol 1995; 9: 221-8
45. Couzinet B, Pholsena M, Young J, et al. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgcns and clinical status in idiopathic hirsutism. Clin Endocrinol 1993; 39: 157-62
46. Moghetti P, Castello R, Negri C et al. Flutamide in the treatment of hirsutism: Long-term clinical effects, endocrine changes and androgen receptor behaviour. Fertil Steril 1995; 64: 511-7
47. Calandra RS, Purvis K, Naess O, et al. Androgen receptors in the rat adrenal gland. J Steroid Biochem Mol Biol 1978; 9: 1009-15
48. Bèlanger A, Labrie F. Dupont A, et al. Endocrine effects of combined treatment with an LHRH-agonist in association with flutamide in metastatic prostatic carcinoma. Clin Invest Med 1988; 11: 321-6
49. Falsetti L, Gamhera A. Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism. Fertil Steril 1999; 72: 41-6
50. Cusan L, Dupont A, Belanger A, et al. Treatment of hirsutism with the pure anti-androgen flutamide. J Ann Acad Dermatol 1990; 23: 462-9
51. De Leo V, Lanzetta D, D'Antona D, et al. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 99-102
52. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconacole and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999; 84: 1304-10
53. Erenus M, Gühürz O, Durmusoglu F, et al. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Peril Steril 1994; 61: 613-6
54. Falsetti L, Gambera A, Legrenzi L, et al. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999; 141: 361-7
55. Falsetti L, De Fusco D, Eleftheriou G, et al. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecol Endocrinol 1997; 11: 251-7
56. Crownover RL, Holland J, Chen A, et al. Flutamide induced liver toxicity including fatal hepatic necrosis. Int J Radiat Oncol Biol Phys 1996; 34: 911-5
57. Moszowitcz I, Wright F, Vicens M, et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. Steroid Biochem 1986; 20: 757-61
58. Marcondes JA, Waychenberg BL, Ahujamra AG, et al. Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects. Fertil Steril 1990; 53: 40-4
59. Fruzetti F, Bersi C, Parrini D, et al. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 1999; 71: 445-51
60. Grigoriou O, Papadias C, Konidaris S, et al. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial. Gynecol Endocrinol 1996; 10: 119-23
61. Jasonni B, Bulletti C, Nardi S, et al. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17β-estradiol. Fertil Steril 1991; 55: 742-5
62. Fruzzetti F. Treatment of hirsutism: antiandrogen and 5α-R inhibitor therapy. In: Azziz R, Nestler JE, Dewnilly D, editors. Androgen excess disorders in women. Philadelphia: Lippincot-Raven, 1997: 787-97
63. Carmina E, Lobo AR. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. Obstet Gynecol 1991; 78: 845-9
64. Cumming DC, Yang JC, Rebar RW, et al. Treatment of hirsutism with spironolactone. JAMA 1982; 247: 1295-5
65. Barth JH, Cherry CA, Wojnarowska F, et al. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women. J Clin Endocrinol Metab 1989; 68: 966-70
66. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79: 703-6
67. Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finusteride to spironolaetone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80: 233-8
68. Tolino A, Petrone A, Sarnacchiaro F, et al. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 1996; 66: 61-5
69. Erenus M, Yücelten D, Durmusoglu F, et al. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Feril Steril 1997; 68: 1000-3
70. Castello R, Tosi F, Perrone F, et al. Outcome of long-term treatment with the 5-alpha reductase inhibitor finasteride in idiopathic hirsutism. Clinical and hormonal effects during a 1 year course of therapy and 1 year follow up. Feril Steril 1996; 66: 734-40